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SUMMARY. While the HVTN 505 trial showed no overall efficacy of the tested vaccine to
prevent HIV infection over placebo, previous studies, biological theories, and the finding
that immune response markers strongly correlated with infection in vaccine recipients gen-
erated the hypothesis that a qualitative interaction occurred. This hypothesis can be assessed
with statistical methods for studying treatment effect modification by an intermediate re-
sponse variable (i.e., principal stratification effect modification (PSEM) methods). However,
available PSEM methods make untestable structural risk assumptions, such that assumption-
lean versions of PSEM methods are needed in order to surpass the high bar of evidence to
demonstrate a qualitative interaction. Fortunately, the survivor average causal effect (SACE)
literature is replete with assumption-lean methods that can be readily adapted to the PSEM
application for the special case of a binary intermediate response variable. We map this adap-
tation, opening up a host of new PSEM methods for a binary intermediate variable measured
via two-phase sampling, for a dichotomous or failure time final outcome and including or
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excluding the SACE monotonicity assumption. The new methods support that the vaccine
partially protected vaccine recipients with a high polyfunctional CD8+ T cell response, an
important new insight for the HIV vaccine field.
KEY WORDS: HIV vaccine; Principal stratification; Randomized clinical trials; Truncation
by death; Two-phase sampling.
1. Introduction
The HIV-1 pandemic continues to wreak morbidity and mortality in the U.S. and glob-
ally, and a preventive vaccine would be the most effective biomedical tool to end the pan-
demic. The most recent efficacy trial of a candidate HIV-1 vaccine – HVTN 505 – random-
ized 2,496 HIV-1 negative volunteers in 1:1 allocation to the DNA/rAd5 vaccine regimen or
placebo (Hammer et al., 2013). Inoculations were administered at months 0, 1, 3, 6, and
the primary objective compared the rate of HIV-1 infection from 6.5 to 24 months between
the randomized treatment arms. The estimated cumulative incidence over this period was
4.62% (3.15%) in the vaccine (placebo) group, with cumulative incidence ratio 1.46 (95%
CI 0.82 to 2.63, Wald test p = 0.20). Through a 2-phase sampling design, Janes et al. (2017)
studied HIV-1 Envelope-specific CD8+ T cell responses measured by intracellular cytokine
staining 2 weeks after the last vaccination (Month 6.5) as a correlate of subsequent HIV-1
infection through 24 months, and found in vaccine recipients a strong inverse correlation
between CD8+ T cell polyfunctionality score (PFS) and HIV-1 infection (p < 0.001). Fong
et al. (2018) followed up this analysis by studying Envelope-specific IgG antibodies at the
same study visit, and found that antibodies were also inversely correlated with infection
(p < 0.01). Moreover, Fong et al. found a significant interaction, where having both low
antibodies and low PFS was associated with especially high risk.
The surprising strength of these correlates of risk [e.g., estimated cumulative risk 0.160
and 0.034 for vaccinated subgroups with PFS below and above the median response, re-
spectively, which was above and below the estimated cumulative risk of 0.070 for placebo
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recipients (Figure 4 of Janes et al.)] suggests the possibility that a qualitative interaction
occurred, where some marker-defined vaccinated subgroups received partial protection from
vaccination whereas others had their risk increased by vaccination. In addition, two previous
efficacy trials of a candidate HIV-1 vaccine that included the same type of vaccine com-
ponent (rAd5) showed increased risk of infection by vaccination among participants with a
specific baseline biomarker value, based on significant interaction tests (Huang et al., 2015
and references therein). Moreover, the identified PFS and antibody marker correlates of risk
are components of known or putative mechanisms of vaccine protection for several licensed
vaccines (Plotkin, 2008), suggesting biological plausibility of a possible qualitative interac-
tion in HVTN 505 based on these markers.
The observations in Janes et al. and Fong et al. of intermediate risk of the placebo
group between that of the marker response-defined vaccinated subgroups does not consti-
tute credible evidence of causal vaccine vs. placebo effect modification across the marker
response subgroups, because post-randomization selection bias could occur (e.g., Frangakis
and Rubin, 2002). For example, if a genetic factor correlates with the ability of the vaccine
to make a high PFS, and this genetic factor is also prognostic for HIV infection, then the
observed differences may not reflect a vaccine vs. placebo causal effect. A proper assess-
ment that does directly assess a causal vaccine effect (eliminating possible selection bias)
would compare risk for each marker response vaccinated subgroup to that of the placebo
recipient subgroup who would have had the same marker response value if assigned vac-
cination, which essentially repeats the primary analysis of vaccine efficacy (which is valid
based on the randomization) across the marker-defined subgroups – such analysis may be
referred to as “principal stratification effect modification (PSEM) analysis” or “principal
surrogate analysis” (Frangakis and Rubin, 2002). Other causal investigations are of equal
interest, such as assessment of the markers as mediators of vaccine efficacy or as surrogate
endpoints for HIV infection. These analyses tackle distinct questions from effect modifi-
cation – namely studying the markers as mechanisms of efficacy and as valid replacement
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endpoints, respectively (e.g., vanderWeele (2015) and Gilbert et al. (2015)) – and our scope
is solely the study of effect modification, which is appropriately tackled by PSEM meth-
ods. A common criticism of PSEM methods is that the subgroups for inference depend on
values of both intermediate response endpoints under each treatment assignment, such that
no participants have known membership in the subgroups for inference, precluding public
health actions/decision-making for subgroups (e.g., Joffe, 2011). However, this problem is
ameliorated for HVTN 505, because only marker response values if assigned to vaccine are
needed, such that PSEM inferences are interpretable in terms of how vaccine efficacy varies
over observable subgroups of vaccine recipients. The interpretation of these inferences is
essentially the same as those for the very common objective in randomized trials to assess
how treatment efficacy varies over baseline subgroups.
However, available PSEM methods make strong structural risk assumptions that do not
hold in our study, and/or require study design augmentations such as close-out placebo vac-
cination to measure biomarker response (Follmann, 2006) that were not utilized in HVTN
505. Given the high bar to convince the scientific community of a qualitative interaction,
application of these methods would be inadequate – rather application of assumption-lean
PSEM methods that avoid strong untestable assumptions are needed. Fortunately, the lit-
erature on survivor average causal effect (SACE) methods (e.g., Robins, 1986) is replete
with assumption-lean methods that can be readily adapted to the PSEM application for the
special case of a binary intermediate response variable. We map this adaptation, including
accommodation of the SACE methods to handle the sub-sampling design of the binary re-
sponse variable (e.g., two-phase sampling in HVTN 505), which opens up a host of new
methods for evaluating a binary intermediate response effect modifier. While the PFS and
antibody markers have underlying mixed binary and continuous distributions, investigation
of binary variables based on these markers is important because regulatory agencies often
require thresholds of response for vaccine licensure or for bridging of vaccine efficacy to
new settings (e.g., Plotkin, 2008). The remainder of this article is organized as follows.
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Section 2 summarizes the relevant SACE and PSEM statistical methods literature and their
relationship. Section 3 defines the PSEM target parameters of interest and their mapping
to SACE estimands, and describes identifiability assumptions. Section 4 summarizes how
existing SACE methods of inference can be adapated. Section 5 evaluates the new PSEM
methods in a simulation study, and Section 6 applies these methods to HVTN 505, yielding
new insights. Section 7 concludes with discussion.
2. SACE and PSEM Problem Statements and their Connection
2.1. SACE Methods.
A common objective of randomized clinical trials is to assess the effect of a binary treat-
ment Z on an outcome of interest Y , where Y is only defined or observable for subjects with
a post-randomization intermediate response variable S equal to a certain level (say S = 1).
Because the intermediate response occurs after randomization, a naive comparison of Y be-
tween treatment arms conditional on S = 1 could be misleading. A causal estimand of
interest is the SACE. To formally define the SACE, for each z = 0, 1, let S(z) and Y (z) be
potential outcomes of S and Y if a subject is assigned to treatment Z = z, where S(z) = S
and Y (z) = Y if Z = z is assigned and S(z) and Y (z) are unobserved counterfactuals if
Z = 1− z is assigned. Then the SACE is defined as
SACE ≡ E[Y (1)|S(1) = S(0) = 1]− E[Y (0)|S(1) = S(0) = 1].
The large SACE methods literature includes techniques for nonparametric bounds (Hud-
gens et al., 2003; Imai, 2008), and techniques for sensitivity analysis that estimate the SACE
under a spectrum of selection bias models (Gilbert et al., 2003; Jemiai et al., 2007; Shepherd
et al., 2011; Chiba and vanderWeele, 2011; Tchetgen Tchetgen, 2014), with output often in-
cluding ignorance intervals and estimated uncertainty intervals about the SACE(Vansteelandt
et al., 2006; Richardson et al., 2014). Several of these methods make the SACE monotonicity
assumption [P (S(0) ≤ S(1)) = 1] and several relax this assumption.
2.2. PSEM Methods.
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Another common objective of randomized clinical trials is to assess biomarkers as prin-
cipal surrogate endpoints for the clinical endpoint of interest. This literature was sparked
by Frangakis and Rubin (2002), and, with S∗ denoting an intermediate response endpoint
measured at some fixed time point τ post-randomization and Y denoting the binary clin-
ical endpoint of interest measured after τ , involves inference about the “principal effects”
or “causal effect predictiveness” surface (Gilbert and Hudgens, 2008): CEP (s1, s0) =
h(risk1(s1, s0), risk0(s1, s0)), where riskz(s1, s0) ≡ P (Y (z) = 1|S∗(1) = s1, S∗(0) =
s0, Y
τ (1) = Y τ (0) = 0) for z = 0, 1. Here h(x, y) is a contrast function satisfying
h(x, y) = 0 if and only if x = y and h(x, y) < 0 for x < y, and Y τ (z) is the indicator that
the clinical endpoint occurs by time τ . The principal surrogate evaluation literature includes
frequentist methods based on estimated maximum likelihood (Follmann, 2006; Gilbert and
Hudgens, 2008; Gabriel et al., 2015) or on pseudo-score estimating equations (Huang et al.,
2013), and Bayesian methods (Li et al., 2010). Because the principal stratification framework
is designed for studying effect modification and not for determining a valid replacement (i.e.
surrogate) endpoint (Gilbert et al., 2015), henceforth we refer to the “principal surrogate”
problem as the more general “principal stratification effect modification” (PSEM) problem.
2.3. Connection between SACE and PSEM Methods.
Another common objective of randomized clinical trials is to assess biomarkers as prin-
cipal surrogate endpoints for the clinical endpoint of interest. This literature was sparked
by Frangakis and Rubin (2002), and, with S∗ denoting an intermediate response endpoint
measured at some fixed time point τ post-randomization and Y denoting the binary clin-
ical endpoint of interest measured after τ , involves inference about the “principal effects”
or “causal effect predictiveness” surface (Gilbert and Hudgens, 2008): Interestingly, de-
spite the close relationship between the two problems, the SACE and PSEM literatures have
developed separately. One reason for this is that for the PSEM problem, S∗ is typically cat-
egorical, continuous, or censored continuous, thus entailing inference across a spectrum of
principal stratum subgroups, whereas the SACE problem makes inference for a single prin-
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cipal stratum. Focusing on a single stratum has facilitated development of nonparametric
and semiparametric SACE methods that need only deal with one or a few terms that are
not identified from the observed data, whereas an attempt to apply SACE methods for each
principal stratum defined by a general categorical S∗ would face a much larger number of
non-identified terms that grows with the number of categories. However, there is an impor-
tant special case for which the existing SACE methods can be practically adapted– when S∗
is binary (i.e., S∗ = 1 versus S∗ = 0 denotes positive versus negative or “high” versus “low”
response)– for which only a few principal strata are of interest.
We consider methods assuming either “equal early clinical risk” (EECR) or “early no-
harm monotonicity” (ENHM), where EECR specifies no individual clinical treatment effects
by τ (i.e., P (Y τ (1) = Y τ (0)) = 1) and ENHM specifies no harmful treatment effects
by τ (i.e., P (Y τ (1) ≤ Y τ (0)) = 1). For methods assuming ENHM, we focus on the
special case that Z = 0 is a control condition such as placebo, and there is no variability
of S∗ in subjects assigned to Z = 0, i.e., P (S∗(0) = 0|Y τ (0) = 0) = 1. This “Constant
Biomarker (CB)” case occurs in placebo-controlled preventive vaccine efficacy trials that
only enroll subjects not previously infected with the pathogen under study and for which the
intermediate response endpoint is a readout from a validated bioassay designed explicitly to
only detect an immune response specific to the pathogen under study (Gilbert and Hudgens,
2008); HVTN 505 is a typical example. For methods assuming EECR, we consider both
the special Case CB and the general case where S∗(0) varies and a monotonicity assumption
holds [P (S∗(0) ≤ S∗(1)|Y τ (1) = Y τ (0) = 0) = 1], which states that among participants
who will not develop a clinical event by τ regardless of treatment assignment, none have a
higher biomarker if assigned Z = 0 than if assigned Z = 1. These scenarios are chosen
because they commonly occur in practice and identifiability is relatively easy to achieve.
Under each of the three assumptions [A: EECR, S∗(0) varies], [B: EECR, Case CB],
and [C: ENHM, Case CB], we show how to apply previously developed SACE methods
to the PSEM problem, which for A amounts to inference about CEP (0, 0), CEP (1, 0),
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and CEP (1, 1), and for B and C amounts to inference about CEP (0, 0) and CEP (1, 0).
Additional original contributions of this work for the PSEM literature include: (i) to al-
low relaxing the strong EECR assumption– which has been made for almost all published
methods– to ENHM; and (ii) to provide methods that can be straightforwardly applied for
the common situation in practice where no adequate baseline predictors of S∗ are available
and closeout placebo vaccination was not performed [previous frequentist methods, such as
Follmann (2006) and subsequent work, require at least one of these design augmentations].
Like (i), contribution (ii) largely broadens the set of applications to which PSEM analy-
sis can be done. A third novel development addresses the issue that most SACE methods
do not explicitly accommodate sub-sampling designs (e.g., case-control/two-phase or case-
cohort) for measuring S [Shepherd, Redman, and Ankerst (2009) is one exception, which
we apply here], whereas most PSEM evaluation methods do. Because sub-sampling designs
are normative in PSEM applications, we focus on this setting, with implication that some
of the previously developed SACE methods must be extended. For simplicity we focus on
an adjustment based on inverse probability weighting, but more efficient methods would be
straightforward to implement.
3. Notation, Target Parameters, Identifiability Assumptions
3.1. Additional Notation.
Let W be a vector of baseline covariates measured in everyone, and R be the indicator
of whether the binary endpoint S∗ is measured at τ . We allow S∗ to be missing due either
to design and/or to happenstance reasons outside of the control of the investigator. To fit
the most common applications in clinical trials we assume Y is binary; in the case of a
time-to-event outcome, Y = I(T ≤ t), where T is the time from randomization until the
endpoint subject to right-censoring and t > τ is a fixed time point of interest. Note that S∗
is undefined if T ≤ τ , which we denote as S∗ = ∗.
3.2. Target Parameters for Principal Stratification Effect Modification.
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Our goal is inference about CEP (0, 0), CEP (1, 0), and CEP (1, 1), where the last pa-
rameter is only relevant in scenario A where S∗(0) is non-constant. Three criteria for a
useful intermediate response endpoint that have been discussed include average causal ne-
cessity (ACN) and average causal sufficiency (ACS) (Gilbert and Hudgens, 2008), as well
as wide variability of CEP (s1, s0) across marker values (effect modification). For scenar-
ios B and C these conditions amount to CEP (0, 0) = 0 (ACN), CEP (1, 0) 6= 0 (ACS),
and CEP (1, 0) largely different from CEP (0, 0). Under Case CB and assumptions A1–A4
defined in the next section, ACN and ACS both hold if and only if the binary intermediate
endpoint satisfies the Prentice (1989) definition of a valid surrogate/replacement endpoint
(Gilbert et al., 2015). Because a valid Prentice surrogate is very useful in practice, checking
this definition is a useful application of the methods.
Define overall risks riskz ≡ P (Y (z) = 1|Y τ (1) = Y τ (0) = 0) for z = 0, 1, and note
riskz = p(0, 0)riskz(0, 0) + p(1, 0)riskz(1, 0) + p(1, 1)riskz(1, 1) for z = 0, 1, (1)
where p(s1, s0) ≡ P (S∗(1) = s1, S∗(0) = s0|Y τ (1) = Y τ (0) = 0) for (s1, s0) ∈ {(0, 0),
(1, 0), (1, 1)}. [Equation (1) uses the fact that p(0, 1) = 0 under the assumptions we use.]
These p(·, ·)’s measure the prevalence of intermediate response subgroups in the early always
survivors (EAS) principal stratum defined by {Y τ (1) = Y τ (0) = 0}.
The riskz and riskz(s1, s0) parameters measure risks in subsets of the EAS principal
stratum; for scenario C we will also consider parameters measuring risks in subsets of the
‘early protected’ (EP) principal stratum defined by {Y τ (1) = 0, Y τ (0) = 1}: riskEPz (s1, s0)
≡ P (Y (z) = 1|S∗(1) = s1, S∗(0) = s0, Y τ (1) = 0, Y τ (0) = 1) and the marginal risks
for z = 1 defined as mrisk1 ≡ P (Y (1) = 1|Y τ (1) = 0) and mrisk1(s1) ≡ P (Y (1) =
1|Y τ (1) = 0, S∗(1) = s1) for s1 = 0, 1.
The observation motivating this work is that a contrast in risk1 and risk0 is a standard
SACE (with intermediate event S = 1 − Y τ ), a contrast in risk1(0, 0) and risk0(0, 0) is a
standard SACE (with intermediate event S = [1 − Y τ ][1 − S∗]), a contrast in risk1(1, 1)
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and risk0(1, 1) is a standard SACE (with intermediate event S = [1− Y τ ]S∗), and, whereas
a contrast in risk1(1, 0) and risk0(1, 0) is not a standard SACE, these two parameters are
identified from (1) and the other parameters. Thus any two existing SACE methods can be
employed to estimate the two sets of means/probabilities {risk1, risk0} and {risk1(0, 0),
risk0(0, 0)}, and another for {risk1(1, 1), risk0(1, 1)} in scenario A, and then equation (1)
is applied to yield estimates of the remaining two probabilities {risk1(1, 0), risk0(1, 0)} via
riskz(1, 0) = [riskz − p(0, 0)riskz(0, 0)− p(1, 1)riskz(1, 1)] /p(1, 0). (2)
The case of an additive contrast function h(x, y) = x−y represents the traditional SACE
estimands, for which we have
CEP (0, 0) = SACE(0, 0) = risk1(0, 0)− risk0(0, 0) (3)
CEP (1, 1) = SACE(1, 1) = risk1(1, 1)− risk0(1, 1) (4)
CEP (1, 0) =
1
p(1, 0)
[SACEmar − p(0, 0)SACE(0, 0)− p(1, 1)SACE(1, 1)] , (5)
where SACEmar ≡ risk1 − risk0. However, we develop the results in terms of pairs of
risks, in order that they apply for general contrast functions. In Case CB the above formulas
simplify, with {risk1(1, 1), risk0(1, 1)} and CEP (1, 1) vanishing.
3.3. Assumptions.
Throughout we make a baseline set of assumptions made in essentially all previous fre-
quentist SACE papers. We assume the (Zi,Wi, Ri, Y τi (1), Y
τ
i (0), S
∗
i (1), S
∗
i (0), Yi(1), Yi(0)),
i = 1, . . . , n, are iid [with observed data Oi = (Zi,Wi, Ri, RiS∗i , Y
τ
i , Yi), with S
∗
i only ob-
served if Ri = 1] and assume A1 SUTVA (Stable Unit Treatment Value Assumption); A2
Ignorable Treatment Assignment: Conditional on W , Z is independent of (Y τ (1), Y τ (0),
S∗(1), S∗(0), Y (1), Y (0)); and A3 No Censoring or Random Censoring: If Y is binary, Y is
observed for all subjects; if Y is time-to-event, right-censoring C(z) is random conditional
on W (T (z) ⊥ C(z)|W for z = 0, 1). As noted above, we develop the methods under
each of two assumptions regarding early clinical events before the intermediate endpoint is
measured at τ :
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A4 Equal Early Clinical Risk (EECR): P (Y τ (1) = Y τ (0)) = 1
A4′ Early No-Harm Monotonicity (ENHM): P (Y τ (1) ≤ Y τ (0)) = 1
For each of A4 and A4′ we also assume p(1, 0) > 0, which holds trivially for any PSEM
evaluation application of interest. A4′ is a standard SACE monotonicity assumption for
the analysis of {risk1, risk0}, which weakens the EECR assumption made in Gilbert and
Hudgens (2008) and almost all subsequent PSEM evaluation papers. This weakening is
practically important, given that for many applications EECR is not plausible. A4 and A4′
have implications that can be tested by comparing the rates of Y = 1 by τ between the two
treatment arms.
For scenario A where S(0) varies we also reduce the number of non-identified terms via
a marker monotonicity assumption:
A5 Marker Monotonicity: P (S∗(0) ≤ S∗(1)|Y τ (1) = Y τ (0) = 0) = 1.
Based on the above stated assumptions, the scenarios under which we develop the meth-
ods can be re-stated as [A: A1–A5, S(0∗) varies], [B: A1–A4, Case CB], and [C: A1–A3,
A4′, Case CB].
3.4. Identifiability of CEP (s1, s0).
We now consider identifiability of CEP (s1, s0), highlighting how A4′, A4, A5, and
Case CB reduce the number of non-identified terms. In this section we describe the number
of fixed sensitivity parameters that are needed to achieve nonparametric identifiability, and
in the next section give examples of how specific models under two SACE methods provide
identifiability.
A1–A3, A5, S(0) varies. We start with a slightly weaker assumption set than sce-
nario A. Our objective is to estimate the three CEP (s1, s0) parameters [for (s1, s0) ∈
{(0, 0), (1, 0), (1, 1)}], by estimating each of the three risk pairs {risk1(0, 0), risk0(0, 0)},
{risk1(1, 1), risk0(1, 1)}, and {risk1(1, 0), risk0(1, 0)}. Because (Y τ (1), S∗(1)) and
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(Y τ (0), S∗(0)) are never both observed, these risk pairs are not identified from A1–A3, A5.
Following Shepherd et al. (2011), without additional assumptions 3 sensitivity parameters
are needed to nonparametrically identify each of the three risk pairs, totaling 9 sensitivity
parameters. For example, define
pi(s1, s0) ≡ P (S∗(1) = s1, S∗(0) = s0, Y τ (1) = Y τ (0) = 0),
pi1(s1, s0) ≡ P (S∗(1) = s1, Y τ (1) = 0|S∗(0) = s0, Y τ (0) = 0, Y (0) = 1),
pi0(s1, s0) ≡ P (S∗(0) = s0, Y τ (0) = 0|S∗(1) = s1, Y τ (1) = 0, Y (1) = 1).
Then {risk1(0, 0), risk0(0, 0)}, {risk1(1, 1), risk0(1, 1)}, and {risk1(1, 0), risk0(1, 0)} are
identified by the three triplets of parameters {pi(0, 0), pi1(0, 0), pi0(0, 0)}, {pi(1, 1), pi1(1, 1),
pi0(1, 1)}, and {pi(1, 0), pi1(1, 0), pi0(1, 0)}, respectively. From equation (1), each riskz for
z = 0, 1 is also identified by these 9 sensitivity parameters because p(s1, s0) = pi(s1, s0)/
{pi(0, 0) + pi(1, 1) + pi(1, 0)}. Other sensitivity parameterizations can also achieve identifia-
bility, but at least 9 sensitivity parameters will still be required.
Under A1–A3, A4′, A5, S(0) varies. Adding A4′ to A1–A3 and A5, pi(1, 1) and risk0(1, 1)
are nonparametrically identified as P (S∗(0) = 1, Y τ (0) = 0) and P (Y (0) = 1|S∗(0) =
1, Y τ (0) = 0). Therefore, identifying risk1(1, 1) requires only one sensitivity parame-
ter, pi0(1, 1). Identifying riskz(0, 0) for z = 0, 1 requires specifying three parameters,
{pi(0, 0), pi1(0, 0), pi0(0, 0)}. Once pi(0, 0) is specified, pi(1, 0) is identified as pi(1, 0) =
P (S∗(0) = 0, Y τ (0) = 0) − pi(0, 0); also everyone with {S∗(0) = 0, Y τ (0) = 0} who
does not have {S∗(1) = 0, Y τ (1) = 0} has to have {S∗(1) = 1, Y τ (1) = 0}, and therefore
specifying pi1(0, 0) also fixes pi1(1, 0) = 1− pi1(0, 0) and thus identifies risk0(1, 0). Hence,
only one additional sensitivity parameter, pi0(1, 0), is needed to identify risk1(1, 0), bringing
the total number of sensitivity parameters to 5.
Under A1–A5, S(0) varies [Scenario A]. Strengthening A4′ to A4, pi(1, 1) and risk0(1, 1)
are still nonparametrically identified, and identification of risk1(1, 1) still requires only one
sensitivity parameter, pi0(1, 1). This same sensitivity parameter also identifies risk1(1, 0) as
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pi0(1, 0) = 1 − pi0(1, 1) because by A4 everyone with (S∗(1) = 1, Y τ (1) = 0) must have
Y τ (0) = 0. Then pi(0, 0) and risk1(0, 0) are also nonparametrically identified. Therefore, to
identify risk0(0, 0) only the sensitivity parameter pi1(0, 0) needs to be specified. As before
under A4′, specifying pi1(0, 0) also identifies risk0(1, 0). Hence a total of two sensitivity
parameters are needed in scenario A.
Under A1–A4, Case CB [Scenario B]. Scenario B is similar to scenario A except that
now the cell (S∗(0) = 1, S∗(1) = 1, Y τ (0) = 0, Y τ (1) = 0) is empty. This implies that
riskz(1, 1) is undefined, for z = 0, 1. Also, in addition to risk1(0, 0) being identified,
risk1(1, 0) is now also nonparametrically identified. Similar to scenario A, risk0(0, 0) is
identified with a sensitivity parameter pi1(0, 0) which then also identifies risk0(1, 0). There-
fore, only one sensitivity parameter is needed for scenario B.
Under A1–A3, A4′, Case CB [Scenario C]. Identifiability is more challenging when re-
laxing A4 to A4′, as 3 sensitivity parameters (e.g., pi(0, 0), pi0(0, 0), and pi1(0, 0)) are needed
to identify {risk1(0, 0), risk0(0, 0)}. The sensitivity parameters pi(0, 0) and pi1(0, 0) also
identify risk0(1, 0). Moreover, one additional sensitivity parameter, pi0(1, 0), is required to
identify risk1(1, 0).
3.5. Mapping Existing SACE Methods to Estimate Target Parameters.
As mentioned in Section 2.2, contrasts of the various risk parameters can be estimated
using SACE methods by appropriately defining the intermediate endpoint S and applying
methods that correspond to the implied monotonicity assumptions in S (written as P [S(1) ≤
S(0)] = 1) based on the specific scenario. Table 1 summarizes how SACE methods in
general can be used to estimate CEP (s1, s0) for scenarios A, B, and C.
Under scenario A, SACEmar is nonparametrically identified by A4. A contrast in
risk1(0, 0) and risk0(0, 0) (i.e., SACE(0, 0)) can be estimated using a standard SACE
method under the assumption of monotonicity with intermediate event S = (1−Y τ )(1−S∗).
Similarly, a contrast in risk1(1, 1) and risk0(1, 1) (i.e., SACE(1, 1)) can also be estimated
with a standard SACE method under monotonicity but now with the intermediate event
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Table 1: Use of SACE Methods [With Numbers of Required Sensitivity Parameters (S.P.s)]
for Estimation of CEP (s1, s0) for (s1, s0) = (0, 0), (1, 0), (1, 1)
Assumption Sets
Target Parameter [A: A1–A5, [B: A1–A4, [C: A1–A3, A4′,
S(0) varies] Case CB] Case CB]
SACEmar(risk1, risk0) Nonpar. Nonpar. Any SACE
riskz ≡ ident. ident. method w/
P (Y (z) = 1|S(1) = S(0) = 1) monot. A4′a
w/ S ≡ 1− Y τ (0 S.P.s) (0 S.P.s) (1 S.P.)
SACE(0, 0)(risk1(0, 0), risk0(0, 0)) Any SACE Any SACE Any SACE
riskz(0, 0) ≡ method w/ method w/ method w/o
P (Y (z) = 1|S(1) = S(0) = 1) monot. A5b,c monot. A5c monot.d
w/ S ≡ [1− Y τ ][1− S∗] (1 S.P.) (1 S.P.) (3 S.P.s)
SACE(1, 1)(risk1(1, 1), risk0(1, 1)) Any SACE N/A N/A
riskz(1, 1) ≡ method w/ N/A N/A
P (Y (z) = 1|S(1) = S(0) = 1) monot. A5e N/A N/A
w/ S ≡ [1− Y τ ]S∗ (1 S.P.) N/A N/A
Mixing parameters Nonpar. Nonpar. Nonpar.
p(0, 0), p(1, 0), p(1, 1) ident. ident. ident.
(0 S.P.s) (0 S.P.s) (0 S.P.s)
aThe monotonicity assumption for the SACE method is P (S(0) ≤ S(1)) = 1 with S ≡ 1− Y τ .
This assumption is A4′, which holds for all scenarios A, B, C.
bThe monotonicity assumption for the SACE method is P (S(1) ≤ S(0)) = 1 with
S ≡ [1− Y τ ][1− S∗].
cBecause of A4 in scenarios A, B, the monotonicity assumption expressed in footnote b simplifies to
P (S∗(0) ≤ S∗(1)|Y τ = 0) = 1, which holds by A5 in scenario A and by Case CB in scenario B.
dUnder A4′ and Case CB in scenario C, the monotonicity assumption expressed in footnote b
amounts to the assumption that no Z = 1 participants with a negative marker response at τ would be
protected by τ . This assumption is often difficult to justify and hence we do not consider methods
making this assumption.
eThe monotonicity assumption for the SACE method is P (S(0) ≤ S(1)) = 1 with S ≡ [1− Y τ ]S∗.
Because of A4 in scenario A, the monotonicity assumption expressed in footnote d simplifies to
P (S∗(0) ≤ S∗(1)|Y τ = 0) = 1, which holds by A5 in scenario A.
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S = (1 − Y τ )S∗. The mixing parameters, p(s1, s0), are all nonparametrically identified
so a contrast in risk1(1, 0) and risk0(1, 0) can be estimated from the other risk parameters
and the mixing parameters based on equation (1).
Estimation under scenario B is identical to that of scenario A except that risk1(1, 1) and
risk0(1, 1) vanish (because the principal stratum defined by [1− Y τ (0)]S(0)∗ =
[1− Y τ (1)]S(1)∗ = 1 is empty), simplifying estimation. Lastly, for scenario C, one can esti-
mate SACEmar using a standard SACE method assuming monotonicity with the intermediate
event S = 1−Y τ . A contrast in risk1(0, 0) and risk0(0, 0) can be estimated using a standard
SACE method that does not assume monotonicity. And, as with scenario B, risk1(1, 1) and
risk0(1, 1) vanish, thereby simplifying estimation of risk1(1, 0) and risk0(1, 0).
Standard SACE methods focus inference on a single principal stratum: CEP (s1, s0) for
a fixed (s1, s0). However, if we make inference on contrasts in the CEP (s1, s0), such as µ ≡
CEP (1, 0)−CEP (0, 0), then our set-up constrains µ to values narrower than the maximum
possible range -2 to 2. For example, for scenario B, setting β0 = 0 implies risk0(1, 0) =
risk0(0, 0), which leaves each of CEP (1, 0) and CEP (0, 0) free to vary over the maximum
possible range as for any standard SACE method but constrains µ to -1 to 1. Thus making
inference on contrasts of CEP (s1, s0) does not achieve just-nonparametric identifiability as
does inference on the individual CEP (s1, s0) parameters. This should be borne in mind
when inference is made on CEP contrasts as well as on the individual parameters.
4. Estimation of the Target Parameters Using SACE Methods
SACE methods provide estimators of the two means constituting each SACE. For con-
creteness, for each scenario A–C we show how the estimation works using Shepherd, Gilbert,
and Dupont’s (2011) SACE method, which in scenarios A, B simplifies to a SACE method
described in several papers including Gilbert, Bosch, and Hudgens (2003) (henceforth GBH)
and Hudgens and Halloran (2006). For simplicity and generality we focus on inverse proba-
bility weighting (IPW) extensions of existing SACE methods. Also for simplicity, we focus
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on semiparametric efficient estimators given the data (Z,R, Y τ , S∗, Y ) not including base-
line covariates W , which amount to sample means with or without IPW as needed. More-
over, we focus on the case that Y is binary and not subject to right-censoring; Web Appendix
B summarizes how the methods translate to Y = I(T ≤ t) with T subject to right-censoring
before t. We use general estimating function notation so that users preferring to use more
efficient estimators leveraging information in W [e.g., Zhang et al. (2008); van der Laan and
Rose (2011)] may substitute alternative estimating functions into the estimating equations.
4.1. General IPW Estimation.
The SACE estimators involve estimation of identified terms E[Y |S = 1, Z = z] for
subgroups S = 1 [with S = 1 − Y τ , (1 − Y τ )S∗, or (1 − Y τ )(1 − S∗)] and of terms
E[S∗|Y τ = 0, Z = z], where S∗ is measured at time τ and is subject to missingness. Define
the probability of observing S∗ as pi(O) ≡ P (R = 1|O), where O is observed data, i.e.,
(Z,W, Y τ , Y ). We assume S∗ is missing at random, pi(O) = P (R = 1|O, S∗), and that
pi(O) is bounded away from zero, pi(O) ≥ ε with probability 1 for some fixed ε > 0.
Following standard IPW estimation, we specify a model pi(O,ψ) for pi(O) (e.g., logistic
regression), and estimate the unknown parameter ψ by maximum likelihood, yielding pii =
pi(Oi, ψ̂). Efficiency and robustness may be improved by calibrating the estimated weights
pii(Wi) accounting for Wi (e.g., Robins, Rotnitzky, and Zhao, 1994; Rose and van der Laan,
2011; Saegusa and Wellner, 2013).
4.2. Dichotomous Outcome SACE Methods Under Scenario A.
For scenario A, the first step is to estimate the terms that are nonparametrically identified–
{risk1, risk0}, p(0, 0), p(1, 0), and p(1, 1). Each riskz for z = 0, 1 can be estimated by any
preferred method for estimating a mean, most simply by solving
∑n
i=1 U
0z
i (Oi; riskz) = 0
with estimating function U0z(Oi; riskz) ≡ (1− Y τi )I(Zi = z)(Yi − riskz).
Given p(0, 0) = P (S∗ = 0|Z = 1, Y τ = 0), if full data were available, then a simple
approach would estimate p(0, 0) by solving
∑n
i=1 U
01
i (Oi; p(0, 0)) = 0 with estimating func-
tion U01(Oi; p(0, 0)) ≡ (1− Y τi )Zi(1− S∗i − p(0, 0)), with convention U01(Oi; p(0, 0)) = 0
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if S∗i = ∗. The IPW version of this equation is
∑n
i=1RiU
01
i (Oi; p(0, 0))/pi(Oi, ψ̂) =
0. The parameter p(1, 1) may be estimated similarly by solving
∑n
i=1RiU
00
i (Oi; p(1, 1))/
pi(Oi, ψ̂) = 0 with U00i (Oi; p(1, 1)) ≡ (1 − Y τi )(1 − Zi)(S∗i − p(1, 1)), again with con-
vention U00i (Oi; p(1, 1)) = 0 if S
∗
i = ∗. With p̂(0, 0) and p̂(1, 1), we then set p̂(1, 0) =
1− p̂(0, 0)− p̂(1, 1).
Lastly, we estimate each pair {risk1(0, 0), risk0(0, 0)} and {risk1(1, 1), risk0(1, 1)}
with a SACE method that assumes monotonicity. For concreteness we summarize how the
GBH method accomplishes this task, and then show how GBH easily extends to accommo-
date IPW.
Standard Semiparametric SACE Method (Notation as in GBH). Consider the odds ratio
selection bias model with user-specified fixed sensitivity parameter β0:
B.0 exp(β0) = P (S(1)=1|S(0)=1,Y (0)=1)/{1−P (S(1)=1|S(0)=1,Y (0)=1)}P (S(1)=1|S(0)=1,Y (0)=0)/{1−P (S(1)=1|S(0)=1,Y (0)=0)} .
Under A1–A3, B.0, monotonicity [P (S(1) ≤ S(0)) = 1], and positivity [P (S(1) = 0, S(0) =
1) > 0, P (S(1) = 1, S(0) = 1) > 0], the two parameters of interest, P 11(z) ≡ P (Y (z) =
1|S(1) = S(0) = 1) for z = 0, 1, are nonparametrically identified. With w0(y;α0, β0) ≡
P (S(1) = 1|S(0) = 1, Y (0) = y) for y = 0, 1, these assumptions equivalently specify
w0(y;α0, β0) = {1 + exp(−α0 − β0y)}−1 for y = 0, 1 (Jemiai et al., 2007).
By monotonicity P 11(1) = P (Y (1) = 1|S(1) = 1), such that P 11(1) is estimated by
solving
∑n
i=1 U
1(Oi;P (Y (1) = 1|S(1) = 1)) = 0 where U1(Oi;P (Y (1) = 1|S(1) =
1)) = ZiSi(Yi − P (Y (1) = 1|S(1) = 1))/
∑n
i=1 ZiSi. Next, P
11(0) is estimated by first
estimating α0 as the solution to
∑n
i=1 U
0(Oi;α0, β0) = 0 where
U0(Oi;α0, β0) = Zi
(
Si − P̂ (S(0) = 1)
1∑
y=0
w0(y;α0, β0)P̂ (Y (0) = y|S(0) = 1)
)
, (6)
where P̂ (Y (0) = 1|S(0) = 1) is obtained in the same way as P̂ (Y (1) = 1|S(1) = 1). Then
with α̂0 from (6), P̂ 11(0) = [P̂ (S(0) = 1)/P̂ (S(1) = 1)]w0(1; α̂0, β0)P̂ (Y (0) = 1|S(0) =
1). We implement this “Standard SACE Method” verbatim multiple times below, with the
17
definition of S (and sometimes Y ) changing for estimating needed terms in CEP (s1, s0).
The Standard SACE Method requires P (S(1) = 1) < P (S(0) = 1) in order that P̂ 11(z)
for each z = 0, 1 has an asymptotic normal distribution and thus to ensure that Wald con-
fidence intervals for P 11(z) based on asymptotic or nonparametric bootstrap variance esti-
mates have correct coverage probabilities (Jemiai et al., 2007). Moreover, if P (S(1) = 1) <
P (S(0) = 1) but the probabilities are close, then the Wald confidence intervals can have poor
coverage. Therefore, the Standard SACE Method only reliably gives correct inference if the
data support P (S(1) = 1) < P (S(0) = 1) with the probabilities not too close. For imple-
mentation of this method for inference on CEP (s1, s0), the needed SACE assumption for C
translated to the binary PSEM problem is A4′′: P (Y τ (1) = 1) < P (Y τ (0) = 1), whereas the
needed SACE assumption for A,B is A5′: P (S∗(0) = 1|Y τ = 0) < P (S∗(1) = 1|Y τ = 0).
Fortunately, both assumptions hold for many real binary PSEM data applications. A5′ essen-
tially always holds, given that it is typically only interesting to study a binary marker as an
effect modifier if it has a higher response rate in the active treatment arm 1 compared to the
control arm 0. A4′′ typically holds in applications where the assumptions C hold, given that
C is motivated by applications where there is demonstrated or suspected treatment efficacy
by time τ , which is exactly A4′′. Moreover, A4′′ and A5′ are testable such that the conditions
needed to assure valid inference can be checked. In the simulations the required assumption
A4′′ or A5′ holds, and in the example A5′ holds whereas A4′′ is questionable.
Standard SACE Method Accommodation of Inverse Probability Weighting. The esti-
mating equations for P (Y (1) = 1|S(1) = 1), P (Y (0) = 1|S(0) = 1), P (S(1) = 1),
P (S(0) = 1) and α0 are readily extended to include inverse probability weights in the stan-
dard way described above.
Implementing the Standard SACE Method for CEP (s1, s0). The semiparametric MLEs
r̂isk1(0, 0) and r̂isk0(0, 0) are obtained as P̂ 11(1) and P̂ 11(0) described above, respectively,
using S ≡ [1− Y τ ][1− S∗] with B.0 and a fixed β0. The semiparametric MLEs r̂isk1(1, 1)
and r̂isk0(1, 1) are obtained in the same way with S ≡ [1 − Y τ ]S∗, with the wrinkle that
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the monotonicity assumption is in the reverse direction [i.e., P (S(1) ≥ S(0)) = 1] from the
published SACE method. This means that we use the Standard SACE Method reversing the
roles of Z = 1 and Z = 0, leading to a selection bias model w1(y;α1, β1) ≡ P (S(0) =
1|S(1) = 1, Y (1) = y) = {1 + exp(−α1 − β1y)}−1 for y = 0, 1 with sensitivity parameter
β1 defined by exp(β1) =
P (S(0)=1|S(1)=1,Y (1)=1)/{1−P (S(0)=1|S(1)=1,Y (1)=1)}
P (S(0)=1|S(1)=1,Y (1)=0)/{1−P (S(0)=1|S(1)=1,Y (1)=0)} .
The estimate P̂ 11(0) is obtained based on U0(Oi;P (Y (0) = 1|S(0) = 1)) = (1 −
Zi)Si(Yi − P (Y (0) = 1|S(0) = 1))/
∑n
i=1(1 − Zi)Si and P̂ 11(1) is obtained based on
estimating α1 from U1(Oi;α1, β1) =
(1− Zi)
(
Si − P̂ (S(1) = 1)
1∑
y=0
w1(y;α1, β1)P̂ (Y (1) = y|S(1) = 1)
)
, (7)
and setting
P̂ 11(1) = [P̂ (S(1) = 1)/P̂ (S(0) = 1)]w1(1; α̂1, β1)P̂ (Y (1) = 1|S(1) = 1). (8)
By standard estimating equation theory, the above estimators are consistent and asymp-
totically normal for given fixed β0 and β1. To obtain Wald confidence intervals for each
CEP (s1, s0), consistent estimating-function based variance estimators may be used for the
estimates P̂ 11(z) not involving α̂0 or α̂1; e.g., the estimated variance of P̂ 11(1) for the Stan-
dard SACE Method is given by
∑n
i=1
(
Ri/pi(Oi, ψ̂)
) [
U1(Oi; P̂ (Y (1) = 1|S(1) = 1))
]2
.
Influence-function based variance estimates are similarly obtained for the estimates P̂ 11(z)
involving α̂0 or α̂1, by using a vector estimating function and the delta method. For example,
for P̂ 11(1) estimated using equation (7), the four components of the estimating function are
for θ̂ = (α̂1, P̂ (S(1) = 1), P̂ (S(0) = 1), P̂ (Y (1) = 1|S(1) = 1))T , with delta method
applied with g(w, x, y, z) = [x/y]w1(1;w, β1)z. All variance estimation is performed with
the R package geex (Saul and Hudgens, 2017).
To perform a sensitivity analysis, one approach specifies a plausible range [lk, uk] (or
maximum possible) for each sensitivity parameter βk, k = 0, 1. An ignorance interval for
CEP (s1, s0) may be estimated by the span of values between the minimum and maximum
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estimates, obtained by setting β0 and β1 to the boundary values. Using the method of Im-
bens and Manski (2004) and Vansteelandt et al. (2006), a Wald asymptotic (1-α)% estimated
uncertainty interval (EUI) for CEP (s1, s0) may be calculated as in formulas (40) and (41)
of Richardson et al. (2014), using the variance estimates of the minimum and maximum
CEP (s1, s0) estimates. In particular, let ĈEP l(s1, s0) and ĈEP u(s1, s0) be the estimates
of CEP (s1, s0) fixing the sensitivity parameters at the values within a pre-specified plausi-
ble region Γ = [l0, u0] × [l1, u1] of the sensitivity parameter(s) that minimize or maximize
ĈEP (s1, s0), respectively. With σ̂2l and σ̂
2
u consistent estimates of the asymptotic limit-
ing variances of ĈEP l(s1, s0) and ĈEP u(s1, s0), respectively, a (1-α)% EUI is given by
[ĈEP l(s1, s0)− cασ̂l/
√
n, ĈEP u(s1, s0) + cασ̂u/
√
n], where cα satisfies
Φ
(
cα +
(√
n(ĈEP u(s1, s0)− ĈEP l(s1, s0))
)
/max{σ̂l, σ̂u}
)
− Φ(−cα) = 1− α,
where Φ(·) denotes the cdf of a standard normal variate. The same approach can be used to
construct Wald confidence intervals and EUIs for the other scenarios and SACE approaches
described below. Theoretical justification of these EUIs relies on the assumption that the
values γl, γu ∈ Γ that correspond to the ignorance interval for CEP (s1, s0) are the same
for all possible observed data laws (condition (39) from Richardson et al.), which holds in
scenarios A and B and may need validation for scenario C applications.
4.3. Dichotomous Outcome SACE Methods Under Scenario B.
For scenario B, CEP (s1, 0) for s1 = 0, 1 can be estimated exactly as for scenario
A, with one change that SACE(1, 1) vanishes because p(1, 1) = 0. In particular, first
{risk1, risk0} and p(0, 0) are estimated as in scenario A, and then p(1, 0) is estimated as
p̂(1, 0) = 1 − p̂(0, 0). Secondly, {risk1(0, 0), risk0(0, 0)} are estimated as in scenario
A. Lastly, riskz(1, 0) for each z = 0, 1 is estimated via equation (2) plugging in esti-
mates for each term. These steps amount to first estimating risk1(0, 0) by the solution to∑n
i=1 Zi(1 − Y τi )(1 − S∗i )(Yi − risk1(0, 0))/pi(Oi, ψ̂) = 0, with convention that the sum-
mand is zero if S∗i = ∗. Then risk0(0, 0) and risk0(1, 0) are estimated by the solutions to
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the two equations B.0 and r̂isk0 − risk0(0, 0)p̂(0, 0)− risk0(1, 0)p̂(1, 0) = 0; our code for
the simulation study and example are implemented in this manner.
4.4. Dichotomous Outcome SACE Methods Under Scenario C.
We implement a SACE method that relaxes monotonicity by using the sensitivity param-
eter β0 in B.0 plus three additional sensitivity parameters:
B.2 exp(β2) =
risk1(0, 0)/{1− risk1(0, 0)}
risk1(0, ∗)/{1− risk1(0, ∗)}
B.3 exp(β3) =
risk1(1, 0)/{1− risk1(1, 0)}
risk1(1, ∗)/{1− risk1(1, ∗)}
B.4 exp(β4) =
p(1, 0)/{1− p(1, 0)}
P (S∗(1) = 1|0, 1)/{1− P (S∗(1) = 1|0, 1)} ,
where risk1(s1, ∗) ≡ P (Y (1) = 1|S∗(1) = s1, S∗(0) = ∗, Y τ (1) = 0, Y τ (0) = 1) for s1 =
0, 1 and P (S∗(1) = 1|0, 1) ≡ P (S∗(1) = 1|Y τ (1) = 0, Y τ (0) = 1). The estimation steps
are similar to those taken for Scenario B, namely: First, p(1, 0) and P (S∗(1) = 1|Y τ (1) =
0, Y τ (0) = 1) are estimated as the solutions to the two equations B.4 and
P̂ (S∗(1) = 1|Y τ (1) = 0)− p(1, 0)P̂ (Y τ (0) = 0|Y τ (1) = 0)
− P (S∗(1) = 1|Y τ (1) = 0, Y τ (0) = 1){1− P̂ (Y τ (0) = 0|Y τ (1) = 0)} = 0.
Then risk0(0, 0) and risk0(1, 0) are estimated as in scenario B. Finally, risk1(s, 0) and
risk1(s, ∗) are estimated as the solutions to P̂ (Y (1) = 1|Y τ (1) = 0, S∗(1) = s)−
risk1(s, 0)P̂ (Y
τ (0) = 0, S∗(0) = 0|Y τ (1) = 0, S∗(1) = s) − risk1(s, ∗){1 − P̂ (Y τ (0) =
0, S∗(0) = 0|Y τ (1) = 0, S∗(1) = s)} = 0 and either B.2 for s = 0 or B.3 for s = 1.
5. Simulation Study
In the first simulation study, data were simulated under the assumptions of Scenario B
(A1–A4, Case CB). Each simulated data set contained n independent individuals, with po-
tential outcomes and observed random variables generated as follows. First, (Y τ (1), Y τ (0))
was set to (0,0) or (1,1) with probabilities 0.8 and 0.2, respectively. Thus A4 (EECR) holds.
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If Y τ (1) = 1, then Y (0) and Y (1) were set to 1. If Y τ (1) = 0, then (S∗(1), S∗(0)) was set
to (0,0) or (1,0) with probabilities 0.4 and 0.6, respectively, such that Case CB holds.
To evaluate size and power of a test of H0 : CEP (1, 0) = CEP (0, 0) versus H1 :
CEP (1, 0) 6= CEP (0, 0), data were simulated under 13 different assumed values for
CEP (1, 0) − CEP (0, 0), namely −0.6,−0.5, . . . , 0.6. Specifically, if Y τ (1) = 0 and
S∗(1) = S∗(0) = 0, then Y (1) was generated as Bernoulli with mean a and Y (0) as
Bernoulli with mean 0.5. On the other hand, if Y τ (1) = 0 and S∗(1) = 1, S∗(0) =
0, then Y (1) was Bernoulli with mean b and Y (0) was Bernoulli with mean 0.5. Thus
CEP (1, 0) − CEP (0, 0) = b − a for contrast function h(x, y) = x − y. The values of a
ranged from 0.7 to 0.1 by decrements of 0.05 and b increased from 0.1 to 0.7 by increments
of 0.05. Under this parameterization risk0(0, 0) = 0.5 = risk0(1, 0), implying β0 = 0.
To generate the observed data, Z was drawn from a Bernoulli distribution with P (Z =
1) = 0.5, and the vector of observable random variables (Z, Y τ , S∗, Y ) = (Z, Y τ (Z), S∗(Z),
Y (Z)) was determined. Simulations were conducted with and without case-cohort sampling
of S∗. For the latter, membership in the random subcohort was determined by R, a Bernoulli
random variable with mean ν. For individuals with Y τ = 0, S∗ was observed for subcohort
members (i.e., R = 1) and cases (i.e., Y = 1). Thus the observed random vector equaled
(Z, Y τ , Y, R, S∗I(Y τ = 0,max{R, Y } = 1)).
Data sets were generated for all 351 combinations of: n ∈ {400, 800, 1600}; ν ∈ {0.1,
0.25, 1}; and CEP (1, 0)−CEP (0, 0) ∈ {−0.6,−0.5, . . . , 0.6}. For each of these combina-
tions, 2000 data sets of size nwere generated. Analyses used [l0, u0] ∈ {[0, 0], [−1, 1], [−2.5, 2.5]}.
For each simulated data set, CEP (1, 0) − CEP (0, 0) was estimated under the Scenario
B assumption set. The null hypothesis H0 was rejected if and only if the 95% EUI for
CEP (1, 0) − CEP (0, 0) excluded 0. Power was estimated by the proportion of simulated
data sets where H0 was rejected (Figure 1). Empirical type I error was always less than
or approximately equal to the nominal significance level α = 0.05. As expected, power
increased with sample size and decreased as the interval [l0, u0] became wider and as the
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size of the subcohort decreased. Figure 2 shows the average widths of the 95% EUIs
for CEP (1, 0) − CEP (0, 0). The EUIs cover at approximately the nominal rate when
l0 = u0, i.e., when CEP (1, 0) − CEP (0, 0) is identifiable, and are conservative other-
wise. The widths are relatively constant across values of CEP (1, 0) − CEP (0, 0) and in-
crease as the size of the random subcohort decreases. Empirical coverage of the 95% EUIs
are plotted in Web Figure 1 (Web Appendix C). Web Figures 2 and 3 display bias of the
CEP (1, 0) − CEP (0, 0) estimates and ratios of the empirical standard errors (ESE) to the
average of the sandwich variance estimated standard errors (ASE), showing unbiasedness of
both the point and standard error estimators.
The data sets simulated under Scenario B were not analyzed with Scenario A methods
that allow S∗(0) to vary, because, as described in the Introduction, in Scenario B Case CB
is known to be true structurally by the definition of S∗(0). In addition, it is not advisable to
use Scenario C methods because validity requires A4′′: P (Y τ (1) = 1) < P (Y τ (0) = 1) as
discussed in Section 4.2, which can be diagnosed to be dubious for many data sets because
they are generated from a distribution with P (Y τ (1) = 1) = P (Y τ (0) = 1).
In the second simulation study, data were simulated under the assumptions of scenario
C (A1-A3, A4’, Case CB) such that A4 in scenario B failed. First (Y τ (1), Y τ (0)) was set
to (0,0), (0,1), or (1,1) with probabilities 0.7, 0.2, and 0.1, such that A4’ (ENHM) holds. If
Y τ (z) = 1, then Y (z) was set to 1. Similar to the first simulation, if (Y τ (1), Y τ (0)) = (0, 0),
then (S∗(1), S∗(0)) was set to (0,0) or (1,0) with probabilities 0.4 and 0.6. If (Y τ (1), Y τ (0)) =
(0, 1), then S∗(1) was set to 0 or 1 with probabilities 0.4 and 0.6.
To evaluate the power of the test of the same hypotheses as the first simulation, data were
simulated under the same thirteen values of CEP (1, 0) − CEP (0, 0) as before. Random-
ization assignment Z and the observed data were also generated as in the first simulation, for
all 351 combinations of: n ∈ {2000, 4000, 8000}; ν ∈ {0.1, 0.25, 1}; and CEP (1, 0)−
CEP (0, 0) ∈ {−0.6,−0.5, . . . , 0.6}. Analyses used [lj, uj] ∈ {[0, 0], [−0.5, 0.5], [−1, 1]}
for j = 0, 2, 3, 4. As for the Scenario B simulations, all data sets were simulated under no
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Figure 1: Power to reject H0 : CEP (1, 0) = CEP (0, 0) for the simulation study under
Scenario B. Solid black lines denote full cohort and dashed (dotted) lines denote case-cohort
with 10% (25%) random subcohort. Horizontal gray lines denote significance level 0.05.
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Figure 2: Average 95% EUI width for the simulation study under Scenario B. Solid lines
denote full cohort and dashed (dotted) lines denote case-cohort with 10% (25%) random
subcohort.
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selection bias. Results based on 2000 simulated data sets are shown in Figures 3 – 4 and
Web Figure 4 – 6. As for scenario B, power and precision diminished as the interval [l0, u0]
became wider and the subcohort size decreased.
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Figure 3: Power to reject H0 : CEP (1, 0) = CEP (0, 0) for the simulation study under
Scenario C. Solid black lines denote full cohort and dashed (dotted) lines denote case-cohort
with 10% (25%) random subcohort. Horizontal gray lines denote significance level 0.05.
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6. Application: HVTN 505 HIV Vaccine Efficacy Trial
We apply the methods to HVTN 505 for three different binary markers defined based on
the PFS or antibody measurements at Month 6.5 described in the Introduction. These binary
markers S are the indicators of whether (S1) the PFS exceeds the median, (S2) the antibodies
exceed the median, or (S3) either PFS or antibodies exceed the median. For marker S1, 70 of
125 (56%) uninfected vaccinees have S∗ = 1, compared to 5 of 25 (20%) infected vaccinees.
For S2 these rates are 66 of 125 (53%) and 9 of 25 (36%), respectively, whereas for S3 these
rates are 91 of 125 (73%) and 10 of 25 (40%).
Case CB holds in HVTN 505, as it generally does in preventive HIV vaccine efficacy
trials, because biomarker values (which are measures of HIV-specific responses to vaccina-
tion) are zero for those assigned placebo. Given Case CB holds, we conduct the analysis
under assumption scenarios B and C, and thus our goal is inference on CEP (0, 0) and
CEP (1, 0). We use a vaccine efficacy contrast h(x, y) = 1 − x/y such that the analy-
sis assesses V E(0) ≡ CEP (0, 0) and V E(1) ≡ CEP (1, 0), respectively. The scenario
B method requires A5, which trivially holds, and A4 (EECR), which is defensible given
that P̂ (Y τ (1) = 1) = 14/1251 = 0.011 and P̂ (Y τ (0) = 1) = 10/1245 = 0.0080 with
Fisher’s exact test 2-sided p-value of p = 0.54 for a difference. In contrast, the scenario C
method requires A4′, which relaxes A4 but at the cost of adding more sensitivity parame-
ters. In addition, for Wald CIs and EUIs to have nominal coverage under scenario C, A4′′
(P (Y τ (1) = 1) < P (Y τ (0) = 1)) must hold as described in Section 4.2, which does not
seem to be true in this example. Thus scenario B may be the most reasonable, and we focus
on it, but we also apply the method under scenario C for illustration purposes. The methods
are implemented exactly as in the simulation study. Web Appendix D studies why B and C
are essentially equivalent for HVTN 505, where extra simulations suggest that a key part of
the explanation is that P (Y τ (1) = 1, Y τ (0) = 0) is small.
Figure 5 shows the results in terms of ignorance intervals and 95% EUIs under each
of the three ranges of sensitivity parameters specified in the simulations, the top panel for
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Figure 4: Average 95% EUI width for the simulation study under Scenario C. Solid lines
denote full cohort and dashed (dotted) lines denote case-cohort with 10% (25%) random
subcohort.
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V E(1)−V E(0) and the bottom panel for V E(0) and V E(1). First, note that the scenario B
and C methods give very similar results (top panel), with EUIs for the latter method only very
slightly wider (and thus the bottom panel only shows results from the scenario B method).
Second, for the antibody marker S2, there is no evidence for V E modification, with 95%
EUIs about V E(1) − V E(0) always including 0. Third, the results are similar for markers
S1 and S3, where if there is assumed to be no selection bias (left panel), then there is clear
evidence for V E modification (with 95% EUIs for V E(1)− V E(0) comfortably excluding
0), whereas accounting for selection bias makes this result borderline significant with the
EUIs just bordering 0 and depending on the amount of selection bias assumed (middle and
right panels). For the PFS marker S2, V E(1) is estimated to be 0.784, 0.723–0.821, and
0.624–0.844 under the models allowing no, intermediate, and highest degrees of selection
bias, with 95% EUIs 0.572–0.996, 0.483–0.975, and 0.304–0.973, respectively. In addition,
the point estimates of V E(0) are consistently negative, suggesting a qualitative interaction
may have occurred, although the 95% EUIs always include 0 (for all three markers), suggest-
ing no clear evidence of negative vaccine efficacy for vaccine recipients with low immune
response. Overall the results suggest that the vaccine may have conferred some protection
for vaccine recipients with PFS responses exceeding the median, where another efficacy
trial would be needed to verify this result. The HIV vaccine field has “moved on” from the
DNA/rAd5 type of HIV vaccine platform, no longer considering it. Thus these new results
are significant for sounding a note of caution to completely giving up on this approach, in
suggesting that if a new version of the regimen could be invented that induces high PFS
responses in a vastly larger subgroup of vaccine recipients, then it could potentially confer
high enough overall vaccine efficacy to confer worthwhile public health benefit.
7. Discussion
A sizable literature on statistical methods for inference on the survival average causal
effect (SACE) has developed over the past 20 years. Motivated by a need for the HVTN 505
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Figure 5: For HVTN 505, ignorance intervals (solid lines) and 95% EUIs (dashed lines) for
V E(0) = CEP (0, 0) and V E(1) = CEP (1, 0) and V E(1) − V E(0) with binary Month
6.5 marker S∗ defined by the indicator of whether (S1) the PFS exceeds the median, (S2) the
antibodies exceed the median, or (S3) either PFS or antibodies exceed the median. The sensi-
tivity analysis allows β0 and β1 to vary over [l0, u0] = [0, 0], [−0.5, 0.5], or [−1, 1]; circles are
point estimates assuming no selection bias. The top panel shows results for V E(1)−V E(0)
with the black and grey lines (left and right) results for the scenario B and C method, respec-
tively. The bottom panel shows scenario B results for V E(1) and V E(0).
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study, we described how these methods can be adapted to the problem of principal strati-
fication effect modification (PSEM) evaluation in a randomized clinical trial with a binary
intermediate response variable. This provides new tools for PSEM analysis, expanding ap-
plicability to more settings, including: (1) to allow inference under a no negative early treat-
ment effects assumption rather than the much stronger no early treatment effects assumption;
(2) to allow inferences for studies with no adequate baseline predictors of the intermediate
endpoint available and for which closeout placebo vaccination was not performed; and (3) to
accommodate the sub-sampling design of the intermediate endpoint. These extensions were
all needed for HVTN 505, with (1) relaxing a dubious assumption and (2) and (3) fitting the
study design realities. Moreover, the new methods avoid making a strong structural placebo
conditional risk assumption made by most available PSEM methods, which was a necessary
innovation for assessing a qualitative interaction in HVTN 505 given the appropriate skepti-
cism that the DNA/rAd5 vaccine could have both beneficial and detrimental effects despite
having no efficacy overall. The data analysis provides the first direct evidence that vaccinated
subgroups with high CD8+ T cell polyfunctionality score (PFS) responses to DNA/rAd5 vac-
cination had beneficial vaccine efficacy to prevent HIV-1 infection, which supports further
research seeking to re-engineer the vaccine regimen to generate high PFS responses in more
vaccine recipients.
The new PSEM methods were developed under three common assumption scenarios that
occur in randomized trials. An important decision for the analysis of a given data set is
whether to use the scenario B or C method, with difference that the latter relaxes the no early
treatment effects assumption to monotonicity. For data sets with a small estimated value of
P (Y τ (1) = 1, Y τ (0) = 0), our simulations and application show that the methods tend to
give similar results, with the intervals from scenario C being only slightly wider than those
from Scenario B. Because there are many applications where monotonicity is much more
plausible that no early treatment effects, in general the scenario C method may be preferred
unless there is compelling knowledge that no early treatment effects holds.
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Supplementary Materials
Title: Supportive results The supportive results include (A) Application of Chiba and Van-
derWeele’s (2011) SACE method for evaluating a binary principal stratification effect
modifier under Scenarios A and B; (B) Adapting the SACE methods for a time-to-
event outcome with right-censoring; (C) Web Figures 1–6 simulation study results;
(D) Additional Application results; and (E) Complete computer code.
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1 Web Appendix A: Application of Chiba and VanderWeele’s
(2011) SACE Method for Evaluating a Binary Principal
Surrogate Under Scenarios A and B
We show how the simple SACE method of Chiba and VanderWeele (2011) can be applied
to evaluate a binary principal surrogate using an additive contrast h(x, y) = x − y. Define
two sensitivity parameters αk, k = 0, 1, by αk ≡ P (Y (k) = 1|Z = 1, Sk = 1)− P (Y (k) =
1|Z = 0, Sk = 1) with S0 ≡ [1− Y τ ][1− S∗] and S1 ≡ [1− Y τ ]S∗. Then
CEP (k, k;αk) = P (Y = 1|Z = 1, Sk = 1)− P (Y = 1|Z = 0, Sk = 1)− αk (1)
= µ1k − µ0k − αk for k = 0, 1.
A simple approach to estimating each µzk, (z, k) ∈ {(0, 0), (0, 1), (1, 0), (1, 1)}, solves∑n
i=1RiU
0zk
i (Oi;µzk)/pi(Oi, ψ̂) = 0 with U
0zk
i (Oi;µzk) ≡ (1 − Y τi )I(Zi = z)I(S∗ =
k)(Yi−µzk)/nzk. Then, CEP (k, k;αk) is estimated by µ̂1k− µ̂0k−αk where αk is a known
constant fixed by the user. Lastly, plugging the above estimates into equation (2) [or equation
(5)] of the main article yields estimates of risk1(1, 0;α1) and risk0(1, 0;α0), and hence of
CEP (1, 0;α0, α1).
By standard estimating equation theory, the above estimators are consistent and asymp-
totically normal for given fixed α0 and α1. To obtain Wald confidence intervals for each
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CEP (s1, s0;α0, α1), consistent sandwich variance estimators may be used, e.g., the esti-
mated variance of µzk for each k = 0, 1 is given by
∑n
i=1
(
Ri/pi(Oi, ψ̂)
) [
U0zki (Oi; µ̂zk)
]2
.
The estimated variance of ĈEP (1, 0) may be obtained by the delta method.
To perform a sensitivity analysis, the user specifies a plausible range [lk, uk] (or maximum
possible) for each αk, k = 0, 1. An ignorance interval for CEP (s1, s0) may be calculated as
the minimum and maximum estimates (obtained with α0 and α1 set to the boundary values).
Using the method of Imbens and Manski (2004) and Vansteelandt et al. (2006), a Wald
asymptotic (1-α)% estimated uncertainty interval (EUI) for CEP (s1, s0) may be calculated
as in formulas (40) and (41) of Richardson et al. (2014), using the variance estimates of the
minimum and maximumCEP (s1, s0) estimates. This approach requires thatCEP (k, k;αk)
is monotone in αk, which holds by (1). The same approach can be used to construct Wald
confidence intervals and EUIs for the other scenarios and SACE approaches described below.
2 Web Appendix B: Adapting the SACE Methods for a
Time-to-Event Outcome with Right-Censoring
The approach to estimation of CEP (0, 0), CEP (1, 0), and CEP (1, 1) using the published
SACE methods described above is similar if the binary outcome Y is defined as Y ≡ I(T ≤
t) with T subject to right-censoring and t is a fixed time point of interest. The estimating
equations used to estimate the needed terms are the same as those described above, except
that new estimating functions U(Oi; ·) are swapped into the equations that are designed to
handle the right-censoring. For example, consider the first estimating equation in Section 3.2,∑n
i=1 U
0z
i (Oi; riskz) = 0. With Y ≡ I(T ≤ t), the same estimating equation can be used
swapping in the estimating function of the Kaplan-Meier estimator (Reid, 1981) or of the
targeted maximum likelihood estimator of a survival curve (Moore and van der Laan, 2009).
The same type of swap is made for the other estimating equations. As described in Shepherd
et al. (2007, 2011), a modification to the weight functions wz(·;αz, βz) is needed, where now
2
they are indexed by time t: wz(t;αz, βz) = {1+exp(−αz−βzmin(t, ν))}−1, where ν is near
the end of follow-up. In addition, the summation
∑1
y=0w0(y;α0, β0)P̂ (Y (0) = y|S(0) = 1)
in equation (6) of the main article is changed to
∫∞
0
w0(t;α0, β0)P̂ (T (0) ≤ t|S(0) = 1) and
the summation
∑1
y=0w1(y;α1, β1)P̂ (Y (1) = y|S(1) = 1) in equation (7) of the main article
is changed to
∫∞
0
w1(t;α1, β1)P̂ (T (1) ≤ t|S(1) = 1).
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3 Web Appendix C: Additional Figures Showing Results of
the Simulation Study
Web Figure 1. 95% EUI coverage for simulation study under scenario B. Solid line denotes
full cohort, dashed (dotted) line denotes case-cohort with 10% (25%) random subcohort.
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Web Figure 2. Bias for simulation study under scenario B. The middle and lower panels
show bias of the minimum and maximum estimates of CEP (1, 0) − CEP (0, 0) over the
plausible region Γ = [l0, u0] of the sensitivity parameter β0. Solid line denotes full cohort,
dashed (dotted) line denotes case-cohort with 10% (25%) random subcohort.
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Web Figure 3. Ratio of empirical standard error (ESE) to average estimated standard error
(ASE) for simulation study under scenario B. Solid line denotes full cohort, dashed (dotted)
line denotes case-cohort with 10% (25%) random subcohort.
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Web Figure 4. 95% EUI coverage for simulation study under scenario C. Solid line denotes
full cohort, dashed (dotted) line denotes case-cohort with 10% (25%) random subcohort.
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Web Figure 5. Bias for simulation study under scenario C. The middle and lower panels
show bias of the minimum and maximum estimates of CEP (1, 0) − CEP (0, 0) over the
plausible region Γ = [l0, u0] of the sensitivity parameter β0. Solid line denotes full cohort,
dashed (dotted) line denotes case-cohort with 10% (25%) random subcohort.
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Web Figure 6. Ratio of empirical standard error (ESE) to average estimated standard error
(ASE) for simulation study under scenario C. Solid line denotes full cohort, dashed (dotted)
line denotes case-cohort with 10% (25%) random subcohort.
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4 Web Appendix D: Additional Analyses for the Applica-
tion
4.1 Explanation of How the Results of the Application are Very Similar
for the Scenario B and C Methods
In this web appendix we show that under the condition P (Y (0) = 1|Y τ (1) = 1, Y τ (0) =
0) = P (Y (0) = 1|Y τ (1) = 0, Y τ (0) = 0), then the scenario B and scenario Cmethods
are equivalent. The typical estimand of interest in the article, CEP (1, 0)− CEP (0, 0), is a
function of risk1(1, 0), risk1(0, 0), risk0(1, 0), and risk0(0, 0). Under the setup for scenario
C in the application section, we switch the direction of the monotonicity assumption which,
when combined with case CB, identifies risk1(1, 0) and risk1(0, 0). Thus, risk1(1, 0) and
risk1(0, 0) are estimated in exactly the same way for the two scenarios:
r̂isk1(j, 0) = P̂ (Y (1) = 1|S∗(1) = j, S∗(0) = 0, Y τ (1) = 0, Y τ (0) = 0)
= P̂ (Y (1) = 1|S∗(1) = j, Y τ (1) = 0)
= P̂ (Y = 1|S∗ = j, Y τ = 0, Z = 1), j = 0, 1
Therefore the results under each scenario will only differ in estimation of risk0(1, 0) and
risk0(0, 0).
Scenario B. Under scenario B, risk0(1, 0) and risk0(0, 0) are estimated with a SACE method
equivalent to solving the following mixing equations:
exp(β0) =
risk0(0, 0)/(1− risk0(0, 0))
risk0(1, 0)/(1− risk0(1, 0))
and
risk0 = p(0, 0)risk0(0, 0) + (1− p(0, 0))risk0(1, 0),
where risk0 and p(0, 0) are identifiable under the assumptions of scenario B. By EECR, we
estimate:
10
r̂isk0 = P̂ (Y (0) = 1|Y τ (1) = 0, Y τ (0) = 0)
= P̂ (Y (0) = 1|Y τ (0) = 0) = P̂ (Y = 1|Y τ = 0, Z = 0),
which is solved by the estimating equation
∑
i
(1− Zi)(1− Y τi )(Y − risk0) = 0.
In addition, by EECR and Case CB,
p̂(0, 0) = P̂ (S∗(1) = 0, S∗(0) = 0|Y τ (1) = 0, Y τ (0) = 0)
= P̂ (S∗(1) = 0|Y τ (1) = 0) = P̂ (S∗ = 0|Y τ = 0, Z = 1),
which is solved by the estimating equation
∑
i
Zi(1− Y τi )(1− S∗ − p(0, 0)) = 0.
Then risk0(1, 0), and risk0(0, 0) are estimated by solving the mixing equations once β0 is
specified.
Scenario C. Under scenario C, we relax the EECR assumption [P (Y τ (1) = Y τ (0)) = 1] to
ENHM [P (Y τ (1) ≥ Y τ (0)) = 1]. Now, risk0 = P (Y (0) = 1|Y τ (1) = Y τ (0) = 0) is no
longer identifiable. So first, an intermediate SACE method must be performed to estimate
risk0, and then the same SACE method as above is performed to estimate risk0(1, 0) and
risk0(0, 0). We can write mixing equations in a similar form to those in the previous section
(with some slight abuse of notation in defining β1 as compared to the main text):
exp(β1) =
risk0/(1− risk0)
P (Y (0) = 1|Y τ (1) = 1, Y τ (0) = 0)/(1− P (Y (0) = 1|Y τ (1) = 1, Y τ (0) = 0))
11
and
P (Y (0) = 1|Y τ (0) = 0) = P (Y τ (1) = 0|Y τ (0) = 0)risk0
+ P (Y τ (1) = 1|Y τ (0) = 0)P (Y (0) = 1|Y τ (1) = 1, Y τ (0) = 0)
where P (Y τ (1) = 1|Y τ (0) = 0) = 1 − P (Y τ (1) = 0|Y τ (0) = 0). Note that β1 = 0
expresses the equality P (Y (0) = 1|Y τ (1) = 1, Y τ (0) = 0) = P (Y (0) = 1|Y τ (1) =
0, Y τ (0) = 0). Now, when β1 = 0, we estimate
r̂isk0 = P̂ (Y (0) = 1|Y τ (1) = 1, Y τ (0) = 0)
= P̂ (Y (0) = 1|Y τ (0) = 0) = P̂ (Y = 1|Y τ = 0, Z = 0),
which is found by solving the same estimating equation as in scenario B:
∑
i
(1− Zi)(1− Y τi )(Y − risk0) = 0.
Therefore the estimate for risk0 in scenario C will be the same as that in scenario B when
β1 = 0. In addition, the estimate for p(0, 0) under scenario Cwill be the same as that under
scenario B by monotonicity and Case CB:
p̂(0, 0) = P̂ (S∗(1) = 0, S∗(0) = 0|Y τ (1) = 0, Y τ (0) = 0)
= P̂ (S∗(1) = 0|Y τ (1) = 0) = P̂ (S∗ = 0|Y τ = 0, Z = 1),
which is solved by the same estimating equation:
∑
i
Zi(1− Y τi )(1− S∗ − p(0, 0)) = 0.
After estimating these terms, risk0(1, 0) and risk0(0, 0) are estimated via the same SACE
method described for scenario B. We have shown that when β1 = 0, the estimated risk0
12
and p(0, 0) used in the mixing equations will be the same as those estimated in B. Thus, the
estimated risk0(1, 0) and risk0(0, 0) (as well as the estimate of CEP (1, 0) − CEP (0, 0))
will be the same under both scenarios when β1 = 0.
As β1 moves further away from 0, the estimates for risk0 will become more different
between the two methods, as will the subsequent results. Note that this is different from
what was described in the methods and simulation sections, where the method for scenario
C is more complex due to the monotonicity assumption being in the usual direction.
4.2 Repeating the Application with a new contrast function and a om-
parison of results in the Application for scenarios B or C under
different early infection data distributions
Web Figure 7 shows the identical results as Figure 5, except using a log relative risk contrast
function h(x, y) =log(x/y) and transforming the ignorance interval and EUI limits back to
the V E scale h(x, y) = 1− x/y.
Web Figure 7. For HVTN 505, ignorance intervals (solid lines) and 95% EUIs (dashed lines)
for V E(0) = 1−exp(CEP (0, 0)) and V E(1) = 1−exp(CEP (1, 0)) andRR(1)/RR(0) =
(1 − V E(1))/(1 − V E(0)) with binary Month 6.5 marker S∗ defined by the indicator of
whether (S1) the PFS exceeds the median, (S2) the antibodies exceed the median, or (S3)
either PFS or antibodies exceed the median. The sensitivity analysis allows β0 and β1 to vary
over [l0, u0] = [0, 0], [−0.5, 0.5], or [−1, 1]; circles are point estimates assuming no selection
bias. The top panel shows results for RR(1)/RR(0) with the black and grey lines (left
and right) results for the scenario B and C method, respectively. The bottom panel shows
scenario B results for V E(1) and V E(0).
As described in the application section of the main text, there may be situations where
it is not clear whether the assumptions of scenario B or C hold for the data being used.
We study this issue by simulating the difference in EUI widths for the two scenarios under
13
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various supposed values of P (Y τ (1) = 1, Y τ (0) = 0), which is implicitly assumed to be
0 under Scenario B, but not under scenario C. Each point on the plot in Web Figure 8 is
the average of the differences in EUI widths calculated across 100 simulations. The red line
represents the estimated value of P (Y τ (1) = 1, Y τ (0) = 0) for the HVTN 505 data set
analyzed in the application section.
Web Figure 8. Difference in 95% EUI width for the HVTN 505 application in the main
article for analysis under scenario B versus under scenario C.
For data sets with a small estimated value of P (Y τ (1) = 1, Y τ (0) = 0), we would expect
the two methods to give very similar results, with the intervals from scenario C being only
slightly wider than those from scenario B. For such data sets it may be unclear whether to
analyze under scenario B or scenario C. In general, justification for use of the scenario B
method would need to come from knowledge that the EECR assumption is plausibly true.
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